Formycon AG (CHIX:FYBD) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


CHIX:FYBD Formycon AG CHIX:FYBD
65 GF Score
Price €63.30
GF Value €115.06
! 5 Warning Signs
View Full Analysis

What is Formycon AG Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Formycon AG's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

CHIX:FYBD vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Formycon AG's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Formycon AG Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Formycon AG's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Formycon AG's Margin of Safety % (DCF Earnings Based) falls into.


CHIX:FYBD
65GF Score
Formycon AG CHIX:FYBD
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Formycon AG (CHIX:FYBD) Overvalued in 2026?

Based on GuruFocus' analysis, Formycon AG stock appears to be undervalued. The current stock price of €63.30 is trading 45% below its estimated GF Value™ of €115.06.

Key valuation signals for CHIX:FYBD:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €115.06 vs. price of €63.30 (45% below fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the CHIX:FYBD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Formycon AG Business Description

Address Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152
Formycon AG is an independent developer of high-quality biosimilars, which are follow-on products to biopharmaceutical drugs. The Company focuses on expanding and further developing its scalable biosimilar platform, which includes approved and pipeline products across ophthalmology, immunology, and immuno-oncology. Its key products include FYB201 (ranibizumab), FYB202 (ustekinumab), FYB203 (aflibercept), FYB206 (pembrolizumab), and FYB208 (dupilumab), along with additional biosimilar candidates in various stages of development. The Company generates maximum revenue from Switzerland.
65GF Score

Get the complete analysis for CHIX:FYBD

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€63.30
Price
€115.06
GF Value